- Home
- GALT vs SEVN Comparison
GALT vs SEVN Comparison
Compare GALT & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | SEVN |
|---|---|---|
| Founded | 2000 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 187.6M |
| IPO Year | 2008 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GALT | SEVN |
|---|---|---|
| Price | $2.28 | $8.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.50 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 273.9K | 110.3K |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 13.90% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $29,383,000.00 |
| Revenue This Year | N/A | $27.75 |
| Revenue Next Year | N/A | $4.06 |
| P/E Ratio | ★ N/A | $44.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $7.90 |
| 52 Week High | $7.13 | $12.85 |
Technical Indicators
Market Signals| Indicator | GALT | SEVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 50.43 |
| Support Level | $2.18 | $8.00 |
| Resistance Level | $2.60 | $8.95 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 51.59 | 67.15 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.